Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
VolitionRx Limited VNRX
$1.76
-$0.12 (-6.63%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
119348663.00000000
-
week52high
2.77
-
week52low
1.31
-
Revenue
306392
-
P/E TTM
-4
-
Beta
1.67750800
-
EPS
-0.54000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 10:59
Описание компании
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Maxim Group | Buy | Buy | 23 авг 2022 г. |
| Aegis Capital | Buy | Buy | 15 авг 2022 г. |
| Aegis Capital | Buy | Buy | 16 ноя 2021 г. |
| Cantor Fitzgerald | Overweight | 10 мар 2021 г. | |
| Aegis Capital | Buy | Buy | 25 янв 2021 г. |
| EF Hutton | Buy | 19 дек 2022 г. | |
| Benchmark | Hold | Buy | 01 февр 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Reynolds Cameron John | A | 1444468 | 33375 | 12 янв 2023 г. |
| Futcher Edward | A | 51186 | 5625 | 12 янв 2023 г. |
| Forterre Gael | A | 90675 | 17250 | 12 янв 2023 г. |
| Michel Gaetan | A | 174697 | 27750 | 12 янв 2023 г. |
| Innes Guy Archibald | A | 1570411 | 5625 | 12 янв 2023 г. |
| Batchelor Ann-Louise | A | 40358 | 14625 | 12 янв 2023 г. |
| Micallef Jacob Vincent | A | 203017 | 14625 | 12 янв 2023 г. |
| Kway Jasmine | A | 54390 | 18375 | 12 янв 2023 г. |
| Nguyen Kim | A | 30436 | 5625 | 12 янв 2023 г. |
| Faulkes Martin Charles | A | 1651693 | 14625 | 12 янв 2023 г. |
Новостная лента
VolitionRx reports cash and cash equivalents of $10M at 1Q-end
Proactive Investors
11 мая 2023 г. в 08:17
VolitionRx (NYSE-A:VNRX) Limited said it had cash and cash equivalents of around $10 million as of March 31, 2023, as it announced financial results and a business update for the first quarter. The company said it received approximately $8 million through an underwritten public offering of its common stock in February, adding that it expects to receive a further $13 million in milestone payments from Heska Corporation and additional funding from three Belgian agencies over the coming months.
VolitionRx posts 240% rise in 2022 revenue; outlines upcoming milestones
Proactive Investors
16 мар 2023 г. в 07:46
VolitionRx Limited (NYSE-A:VNRX) has reported a sharp rise in annual revenue as it ‘shifts gears' towards its goal of becoming a commercial company with products. The company, which is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals, recorded revenue of approximately $300,000 for the year to December 31, 2022, up 240% over the prior year.
VolitionRx Limited Schedules Full Year 2022 Earnings Conference Call and Business Update
PRNewsWire
10 мар 2023 г. в 08:00
Conference call to take place on Thursday March 16 at 08:30 a.m. Eastern Time HENDERSON, Nev.
VolitionRx reveals pricing of its $7.5M public equity offering
Proactive Investors
17 февр 2023 г. в 09:33
VolitionRx (NYSE-A:VNRX) Limited announced that it has priced its underwritten public offering of 4.3 million company common shares at $1.75 per share, with expected gross proceeds to Volition of $7.525 million. The multi-national epigenetics company said it intends to use the net proceeds from the offering for research and continued product development, clinical studies, product commercialization, working capital and other general corporate purposes, including potential strategic acquisitions.
Why Is VolitionRX (VNRX) Stock Down 17% Today?
InvestorPlace
17 февр 2023 г. в 09:08
VolitionRX (NYSEMKT: VNRX ) stock is taking a beating on Friday after the company revealed a proposed public offering for its shares. The big news here is VolitionRX planning a public offering of it VNRX stock.